Primary Application
For what
Blood and Cardiovascular
Immune and Lymphatic
Integumentary
Mitochondrial and Energy Production
Source
Allopathy
For whom
People
All Trans Retinoic Acid (ATRA) is FDA approved in the treatment of promyelocytic leukemia. ATRA is a strong differentiating agent. As such, ATRA has potential as a therapy in a number of cancers, especially in the context of IC medicines. ATRA binds to retinoic acid receptors, and subsequently activates DNA transcription activity to move immature (e.g. malignant) cells toward normal maturation. Consider the use of ATRA in cases of cancer and precancerous lesions, including polyps, actinic keratosis, and others.
Similar ICs
317
44.6 k
12
1.15 k
177
62.1 k
184
118 k
483
145 k
637
140 k
400
54.4 k
228
20.5 k
123
37.4 k
466
81.9 k
Please select language
Select